Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow SNN
Smith & Nephew SNATS, Inc. (SNN) Piotroski F-score
Smith & Nephew SNATS, Inc.'s Piotroski F-score for fiscal 2025 is 7 out of 9: 7 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 7 | 0.00 |
| FY2024 | 7 | 0.00 |
| FY2023 | 7 | (1.00) |
| FY2022 | 8 | 1.00 |
| FY2021 | 7 | 3.00 |
| FY2020 | 4 | 0.00 |
| FY2019 | 4 | (2.00) |
| FY2018 | 6 | (1.00) |
| FY2017 | 7 | 0.00 |
| FY2016 | 7 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 6.01% | 4.05% | Pass | 1 |
| Positive operating cash flow | 1.29b | 987.00m | Pass | 1 |
| Rising return on assets | 6.01% | 4.05% | Pass | 1 |
| Cash flow above net income | 660.00m | 575.00m | Pass | 1 |
| Falling long-term leverage | 0.31 | 0.32 | Pass | 1 |
| Rising current ratio | 2.57 | 2.89 | Fail | 0 |
| No new shares issued | 433,500,000 | 436,500,000 | Pass | 1 |
| Rising gross margin | 68.01% | 69.64% | Fail | 0 |
| Rising asset turnover | 0.59 | 0.57 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 7 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| GMED Globus Medical, Inc. compare | 9 |
| PEN Penumbra, Inc. compare | 8 |
| SNN Smith & Nephew SNATS, Inc. | 7 |
| ZBH Zimmer Biomet Holdings, Inc. compare | 6 |
| PODD Insulet Corporation compare | 6 |
| BIO.B Bio-Rad Laboratories, Inc. compare | 5 |
| BIO Bio-Rad Laboratories, Inc. compare | 5 |
| BRKR Bruker Corporation compare | 4 |
| GKOS Glaukos Corporation compare | 3 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover